Dr. Kathryn Adamiak Davis leads a research lab focused on improving treatment outcomes for patients with drug-resistant epilepsy. The lab investigates the use of biomarkers to predict how well patients will respond to a device called responsive neurostimulation (RNS) that helps control seizures. By analyzing clinical and brain activity data, the lab aims to develop a predictive signature that could guide better treatment decisions for individuals seeking relief from their seizures.

Douglas Epstein's research lab focuses on understanding the genetic causes of adult-onset hearing loss, specifically investigating mutations in the Zfp719 gene. By conducting studies on genetically altered mice and utilizing advanced genomic techniques, the lab aims to identify how these mutations affect inner ear functions and contribute to hearing loss. The research not only seeks to elucidate the biological mechanisms behind this condition but also hopes to pave the way for new therapies and screening methods for high-risk individuals.

Dr. Jonathan A. Epstein's lab at the University of Pennsylvania focuses on designing advanced immune therapies to improve cardiac health. Specifically, the research targets the engineering of T regulatory cells to combat inflammation and fibrosis in the heart after events such as myocardial infarction, which can lead to heart failure. Through innovative techniques like lipid nanoparticle delivery, the lab aims to enhance the healing process and overall heart function.

Dr. Wei Guo's lab at the University of Pennsylvania focuses on understanding exosomes, which are tiny vesicles secreted by cells that play a crucial role in communication between cells. These exosomes carry molecules that can influence how other cells behave, impacting important processes such as cancer progression and immune responses. The lab investigates the mechanisms behind exosome secretion and how this process may be manipulated for therapeutic purposes, including potential cancer treatments.

Dr. Andrea Facciabene leads innovative research at the University of Pennsylvania focusing on cancer treatment, specifically exploring the combination of radiation therapy with T-cell therapy and modifications of the gut microbiome. Their work seeks to enhance antitumor responses in patients with lymphomas and lung cancer, aiming to redefine treatment strategies to prolong patients' survival. By studying how gut bacteria can impact cancer therapies, the lab is at the forefront of novel cancer treatment research that could lead to groundbreaking advancements in oncology.

Dr. Yi Fan's lab at the University of Pennsylvania focuses on understanding glioblastoma, a highly aggressive brain tumor, and how it resists treatments. The research aims to explore the role of specialized cells in the tumor's blood supply and their influence on the immune response, potentially paving the way for innovative therapies that could improve patient outcomes.

Dr. Yong Fan's lab at the University of Pennsylvania focuses on using advanced artificial intelligence and machine learning techniques to study how the brain develops and functions. The research aims to improve our understanding of brain development variability in youth through the analysis of large-scale brain imaging data. By creating interpretable models and tools, the lab seeks to provide insights into individual differences in cognition and psychopathology, ultimately guiding personalized treatment approaches for brain disorders.

Dr. Thomas A. Jongens' lab at the University of Pennsylvania focuses on understanding Fragile X Syndrome, the leading genetic cause of intellectual disability and autism. They use fruit fly and mouse models to study how mitochondrial dysfunction impacts cognitive and behavioral outcomes in Fragile X. Their research aims to identify potential treatments that can improve symptoms, such as the use of metformin and other pharmacological agents that target cellular signaling pathways.

Dr. David Irwin's research lab at the University of Pennsylvania focuses on understanding frontotemporal dementia (FTD), a serious condition that affects younger individuals and leads to significant changes in behavior, personality, and cognitive function. The lab investigates how glial cells and iron accumulation contribute to neurodegeneration in different types of FTD, particularly those influenced by tau or TDP-43 proteins. By analyzing human brain tissue and integrating advanced imaging techniques, the lab aims to uncover patterns that could lead to better diagnosis and treatment options for FTD.

Professor Serge Fuchs leads a lab focused on enhancing the effectiveness of CAR T cell therapy for solid tumors in cancer treatment. His research investigates how the tumor microenvironment suppresses CAR T cells and aims to develop strategies to improve their viability and anti-tumor efficacy. The lab employs various molecular techniques to understand these mechanisms and explore new interventions that could make CAR T therapy more successful against challenging cancer types.

Dr. Xue Gao's lab at the University of Pennsylvania focuses on advancing techniques for precise genome editing, particularly in the context of cardiac diseases like hypertrophic cardiomyopathy (HCM). Through innovative approaches, they are developing controllable base editors that aim to correct genetic mutations with minimal off-target effects, ultimately offering new potential treatments for various conditions. The research explores new methods of delivering these genetic tools to ensure effective and safe applications in living organisms.

Dr. James C. Gee's lab at the University of Pennsylvania focuses on enhancing imaging technologies in biomedical research. Their main project, the Advanced Normalization Tools (ANTs), is an open-source software library that offers powerful tools for image processing and analysis, benefiting researchers across various fields. The lab aims to modernize and expand this toolkit to support complex imaging needs and meet the growing demands of the scientific community.

Dr. Joshua Gold's lab investigates how the brain makes decisions by incorporating feedback from previous experiences. They focus on the interactions between two brain regions, the Anterior Cingulate Cortex (ACC) and the locus coeruleus, to understand how these interactions influence decision-making performance. By observing neuronal activity, the lab aims to uncover the mechanisms behind adaptive decision-making that relates to various mental health disorders.

Dr. Ekaterina L. Grishchuk’s research lab at the University of Pennsylvania focuses on understanding how molecular machines, particularly kinetochores, operate during cell division. The lab studies the mechanics of how chromosomes are segregated, which is crucial for maintaining genetic stability in cells. Through innovative laboratory techniques, they investigate the forces involved in these processes at a molecular level, providing insights that could impact our understanding of various health issues, including cancer and other genomic disorders.

Dr. Roy H. Hamilton's lab at the University of Pennsylvania focuses on the recovery of language abilities in individuals with aphasia, a common condition following stroke, and primary progressive aphasia (PPA), a form of dementia affecting language. The lab investigates the use of non-invasive brain stimulation techniques, specifically transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), to enhance communication therapy. By understanding how brain networks change after injury, the lab aims to develop personalized treatment strategies that improve language recovery outcomes for patients suffering from these language disorders.

Dr. Mohammad Haris's lab focuses on understanding Alzheimer's disease by exploring the role of neuroinflammation and developing new imaging methods to monitor it. Their research aims to connect neuroinflammation to disease progression and metabolic changes in the brain through innovative techniques. By working with mouse models and advanced magnetic resonance spectroscopy methods, they hope to create new diagnostic tools that can improve how we detect and treat Alzheimer's disease.

Dr. Elizabeth Heller's lab studies the effects of epigenetic modifications on behavior, particularly in the context of substance use disorders, such as cocaine addiction. By using innovative techniques like CRISPR for locus-specific epigenetic editing, the lab aims to understand how changes at the molecular level can influence gene expression and behavior, especially in response to stress and drug exposure. The ultimate goal is to uncover potential therapeutic targets to address addiction-related issues.

Dr. Jorge Henao-Mejia's lab at the University of Pennsylvania focuses on understanding how early life exposures, particularly to glucocorticoids (stress hormones), influence the immune system and its response to diseases. They investigate how these exposures can reshape immune cells like monocytes and macrophages, linking them to conditions such as obesity, diabetes, allergies, and cancer. The lab employs advanced methods including genomics and single-cell analysis to uncover the mechanisms by which these changes happen and their implications for health.

Dr. James L. Riley's lab is focused on innovative therapies for HIV, aiming to develop methods that can not only control but potentially cure the infection. They are working on advanced techniques, including engineered T cells and mRNA lipid nanoparticles, to deliver targeted treatments that can help remove the hidden reservoirs of the virus within the body. This research leverages cutting-edge immune engineering and cell therapy to improve patient outcomes for people living with HIV.

Dr. Michael Betts' lab focuses on understanding the mechanisms that allow HIV to persist in infected individuals, which is crucial for developing effective cure strategies. They utilize advanced techniques to analyze the immune response and the characteristics of the HIV reservoir, with the aim of enhancing treatments for people living with HIV. The research seeks to identify potential therapeutic targets to improve immune responses and reduce the viral reservoir in patients.